Barely Significant
← all excerpts

Continuous immunotherapy beyond disease progression in patients with advanced non-small cell and small cell lung cancer.

Cancer Immunol Immunother · 2025 · PMC11861770 · PMID 39998635

Europe PMCDOI
1
hedged sentence
0.1610
closest p · 3.2× alpha
0.1610
boldest claim

The sentences

showed a trendP = 0.161not close (p > 0.1)
However, ORR and DCR were similar between the IBP and NIBP groups, with no statistically significant differences observed, although the IBP group showed a trend toward longer mPFS and mOS than the NIBP group (ORR: 38.7% vs. 12.5%, P = 0.161; DCR: 80.6% vs. 62.5%, P = 0.277, Table 2 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.